Bioage Labs, INC Form 4 insider transactions

Shane Barton, an officer at BioAge Labs, Inc., reported transactions involving the acquisition and disposition of common stock and stock options, executed under a Rule 10b5-1 trading plan.

Director Vijay Satyanand Pande was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.

Director Rekha Hemrajani was granted 22,000 stock options in BioAge Labs, Inc. as part of an equity compensation award.

Director James Healy was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.

Director Patrick G. Enright was granted 22,000 stock options in BioAge Labs, Inc. as part of standard equity compensation.

Director Michael H. Davidson was granted 22,000 stock options in BioAge Labs, Inc. with an exercise price of $15.48.

Director Jean-Pierre Garnier was granted 22,000 stock options in BioAge Labs, Inc. as part of an equity compensation award.

BioAge Labs Chief Financial Officer Dov A. Goldstein exercised options to acquire 3,542 shares of common stock.

BioAge Labs Chief Medical Officer Paul D. Rubin executed trades involving company stock options and common stock under a pre-arranged Rule 10b5-1 plan.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, sold 7,433 shares of common stock for $20.3 per share after exercising options, as part of a pre-arranged 10b5-1 trading plan.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, was granted 110,000 stock options with an exercise price of $19.63, vesting monthly over four years.

BioAge Labs' Chief Operating Officer and Director, Eric Morgen, received grants for 122,500 stock options with an exercise price of $19.63, vesting monthly over four years.

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, was granted 110,000 stock options with an exercise price of $19.63, vesting monthly over four years.

BioAge Labs' CEO, Kristen Fortney, was granted 330,000 stock options with an exercise price of $19.63, vesting monthly over four years.

BioAge Labs' Principal Accounting Officer, Shane Barton, was granted 45,000 stock options with an exercise price of $19.63, vesting monthly over four years.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised stock options and subsequently sold all acquired common stock for a total of $139,368.75, as per a pre-arranged 10b5-1 trading plan.

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, MD, exercised stock options to acquire 3,541 shares of common stock at $4.38 per share.

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, exercised options to acquire 3,542 shares of common stock at $4.38 per share.

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.

BioAge Labs CEO Kristen Fortney sold 233,107 shares of common stock for a weighted average price of $18.1163 per share under a pre-arranged Rule 10b5-1 trading plan.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised options and sold 7,433 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 trading plan.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised stock options and subsequently sold 18,000 shares of common stock for a profit.

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised stock options and subsequently sold 68,897 shares of common stock for approximately $701,800.

BioAge Labs, Inc. Director Vijay Satyanand Pande acquired 22,000 stock options with an exercise price of $4.32, vesting based on future events.

BioAge Labs, Inc. Director Rekha Hemrajani was granted 22,000 stock options with an exercise price of $4.44, vesting on the earlier of the next annual meeting or one year from the grant date.

BioAge Labs, Inc. Director and 10% Owner James Healy was granted 22,000 stock options with an exercise price of $4.44 per share, vesting over the next year.

BioAge Labs, Inc. Director Patrick G. Enright was granted 22,000 stock options with an exercise price of $4.44 per share, vesting over the next year.

BioAge Labs, Inc. director Michael H. Davidson was granted 22,000 stock options with an exercise price of $4.44, aligning his interests with shareholders.

BioAge Labs, Inc. Director Jean Pierre Garnier was granted 22,000 stock options with an exercise price of $4.44, vesting over one year or by the next annual meeting.

Rekha Hemrajani, a director at BioAge Labs, amends a previous SEC Form 4 filing to include a purchase of 3,000 shares of common stock at $18 per share.